SCHEMBL14973239

SCHEMBL14973239

CNc1ccc(-c2noc(-c3cnn(C)c3COc3ccc(C(F)(F)F)cc3)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 1/20 0.41
SPHK2 Q9NRA0 1/20 0.40
FFAR1 O14842 1/20 0.39
S1PR1 P21453 2/20 0.38
CHUK O15111 1/20 0.38
TXNRD1 Q16881 1/20 0.38
NOX4 Q9NPH5 1/20 0.38
PDE2A O00408 2/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
STAT3 P40763 1/20 0.38
HDAC1 Q13547 6/20 0.38
HDAC6 Q9UBN7 6/20 0.38
HDAC5 Q9UQL6 3/20 0.38
HDAC4 P56524 2/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
POLB P06746 1/20 0.37
GSTP1 P09211 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10060103 0.89 SMPD1 (0.44) SMPD1SPHK2FFAR1S1PR1STAT3
SCHEMBL14973304 0.88 LMNA (0.42) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14973237 0.88 KCNT1 (0.42) SMPD1SPHK2S1PR1STAT3HDAC1
SCHEMBL14972955 0.87 SMPD1 (0.40) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14972918 0.87 HDAC1 (0.50) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14972999 0.86 HDAC1 (0.42) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14973249 0.86 CXCR1 (0.46) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14973256 0.86 SMPD1 (0.40) SMPD1SPHK2FFAR1S1PR1CHUK
SCHEMBL14973300 0.86 NR1H4 (0.47) SMPD1FFAR1S1PR1CHUKTXNRD1
SCHEMBL14973330 0.86 CHUK (0.48) SMPD1SPHK2FFAR1S1PR1CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A SMPD1 4077/4885SPHK2 2420/4885FFAR1 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.